Horizon 2020 – COVID19 2nd EOI Call Results Announced
The European Commission this week announced the results from the second COVID-19 call (SC1-PHE-CORONAVIRUS-2020-2). This latest call had a budget of €129.5 million and 23 projects have been short-listed for approval, of which 10 have UK partners. These funds come from Horizon 2020, the EU’s research and innovation programme, as part of the Commission's €1.4 billion pledge to the Coronavirus Global Response.
The 23 projects, which involve 347 research teams from 40 countries in Europe and beyond will work on:-
Rapid Repurposing of manufacturing for vital medical supplies and equipment (€22.1 million). For instance, using injection moulding and additive manufacturing (3D printing); adaptive and resilient production and supply chain methods; and repurposing manufacturing as a service network for fast reaction;
Medical technologies, Digital tools and Artificial Intelligence analytics to improve surveillance and care at high Technology Readiness Levels (€55.2 million). This includes the development of new devices for faster, cheaper and easier diagnosis, often using AI; telemedicine and AI to diagnose and treat people more safely and remotely; new technologies to protect healthcare workers; intensive care and telemedicine; innovation hubs with open call to address and test rapidly emerging ideas;
Behavioural, social and economic impacts of the outbreak responses (€28 million), for instance in depth analysis of responses at the levels of government, public health, community, and information and communications and evaluation of promising approaches; and by examining the dynamics of the outbreak to map and analyse unintended impacts, including on mental health, develop solutions and inclusive guidance for policymakers and health authorities and enhance Europe’s preparedness for future similar events;
Pan-European COVID-19 cohorts (€19.9 million). A major investment will be made for the creation of a new pan-European cohort built on existing and new large-scale population cohorts in European and non-European countries, comprising both infected and non-infected individuals, in order to significantly improve responsiveness to SARS-CoV-2 and provide a model for responsiveness for new public health threats; and
Collaboration of existing EU and international cohorts of relevance to COVID-19 (€3 million) will be enhanced through a coordination and support action to network research institutions collecting data on the provision of care to patients across Europe and internationally, which will enable studies into patient’s characteristics, risk factors, safety and effectiveness of treatments and potential strategies in real settings.